NFATC2 and central nervous system cancer: Unlike in the immune cells with dominant expression of NFATc2, NFATc3 in glioma cells could still interact with calcineurin through an alternative binding site and remain activated despite blocking of the PxIxIT docking site by 11R-VIVIT.